Dubois' Lupus Erythematosus and Related Syndromes

1. Cover image - p. Cover 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Preface - p. iii 6. List of Contributors - p. iii 7. Section 1: What Is Lupus? - p. iii 8. List of Tables - p. iii 9. Chapter 1: History of Lupus - p. iii 10. Chapter 2: Definition and Classification of Lupus and Lupus-Related Disorders - p. iii 11. Chapter 3: The Epidemiology of Lupus - p. iii 12. Section 2: Pathogenesis - p. iii 13. Chapter 4: Overview of Lupus Pathogenesis - p. iii 14. Chapter 5: Genetics of Human SLE - p. iii 15. Chapter 6: Epigenetics of Lupus - p. iii 16. Chapter 7: The Environment and the Host - p. iii 17. Chapter 8: The Innate Immune System in SLE - p. iii 18. Chapter 9: B Cells and Generation of Antibodies - p. iii 19. Chapter 10: T Cells - p. iii 20. Chapter 11: Adaptive and Innate Immunoregulatory Cells - p. iii 21. Chapter 12: Cytokines in Lupus - p. iii 22. Chapter 13: Immunometabolism - p. iii 23. Chapter 14: Animal Models in Lupus - p. iii 24. Section 3: Mechanisms of Tissue Injury - p. iii 25. Chapter 15: Abnormalities in Immune Complex Clearance and Apoptotic Cell Clearance - p. iii 26. Chapter 16: The Role of Complement in SLE - p. iii 27. Chapter 17: Apoptosis and Inflammatory Forms of Cell Death - p. iii 28. Chapter 18: Tissue Damage in Lupus: Free Radicals and Fibrosis - p. iii 29. Chapter 19: Pathogenesis of Fibrosis—The Lung as a Model - p. iii 30. Chapter 20: Pathogenesis of Lupus Nephritis - p. iii 31. Chapter 21: Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus - p. iii 32. Chapter 22: Pathogenesis of Cutaneous Lupus - p. iii 33. Chapter 23: Pathogenesis of Neuropsychiatric Lupus - p. iii 34. Chapter 24: Pathogenesis of Antiphospholipid Antibody Syndrome - p. iii 35. Chapter 25: Pathogenesis of Sjögren's - p. iii 36. Section 4: Autoantibodies - p. iii 37. Chapter 26: Structure and Derivation of Autoantibodies - p. iii 38. Chapter 27: Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes - p. iii 39. Chapter 28: Antibodies Against ENA (Sm, RNP, SSA, SSB) - p. iii 40. Chapter 29: Antibodies Against C1q - p. iii 41. Chapter 30: Antilipoprotein and Antiendothelial Cell Antibodies - p. iii 42. Chapter 31: Drug-Induced Lupus Erythematosus - p. iii 43. Section 5: Clinical Aspects of Lupus Erythematosus - p. iii 44. Chapter 32: Overview and Clinical Presentation - p. iii 45. Chapter 33: Skin Disease in Cutaneous Lupus Erythematosus - p. iii 46. Chapter 34: The Musculoskeletal System and Bone Metabolism - p. iii 47. Chapter 35: Lupus and the Cardiopulmonary System - p. iii 48. Chapter 36: Lupus and the Nervous System: Clinical Aspects, Psychopathology, and Imaging - p. iii 49. Chapter 37: Gastrointestinal and Hepatic Systems - p. iii 50. Chapter 38: Hematologic and Lymphoid Abnormalities in SLE - p. iii 51. Chapter 39: Neonatal Lupus: Pathogenesis and Clinical Approaches - p. iii 52. Chapter 40: Pregnancy and Autoimmune Disease, Reproductive and Hormonal Issues - p. iii 53. Chapter 41: Systemic Lupus Erythematosus in Childhood and Adolescence - p. iii 54. Chapter 42: Clinical Aspects of Antiphospholipid Syndrome - p. iii 55. Chapter 43: Lupus and Infections - p. iii 56. Chapter 44: Ocular, Aural, and Oral Manifestations of Lupus - p. iii 57. Chapter 45: Clinical Aspects of Sjögren's - p. iii 58. Section 6: Assessment of Lupus - p. iii 59. Chapter 46: Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Clinical Laboratory Tests in Systemic Lupus Erythematosus - p. iii 60. Chapter 47: Differential Diagnosis and Disease Associations - p. iii 61. Chapter 48: Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease - p. iii 62. Chapter 49: Clinical Markers, Metrics, Indices, and Clinical Trials - p. iii 63. Chapter 50: Lupus Biomarkers - p. iii 64. Section 7: Management of Lupus - p. iii 65. Chapter 51: Principles of Therapy, Local Measures, and NSAIDs - p. iii 66. Chapter 52: Antimalarial Medications - p. iii 67. Chapter 53: Systemic Glucocorticoid Therapy for SLE - p. iii 68. Chapter 54: Immunosuppressive Drug Therapy - p. iii 69. Chapter 55: Complementary and Alternative Medications, Specialized and Niche Therapies - p. iii 70. Chapter 56: Adjunctive Treatments and Preventive Measures - p. iii 71. Chapter 57: Targeted Therapies in SLE - p. iii 72. Chapter 58: Management of Cutaneous Lupus Erythematosus - p. iii 73. Chapter 59: Epidemiology and Management of Lupus Nephritis - p. iii 74. Chapter 60: Management of Sjögren's - p. iii 75. Section 8: Outcomes - p. iii 76. Chapter 61: Socioeconomic and Disability Aspects - p. iii 77. Chapter 62: Prognosis and Mortality of SLE - p. iii 78. Index - p. iii